Ambrx Analyst & Investor Day: ARX788 in Breast Cancer and ARX517 in Prostate Cancer
About The Event
Join us for a virtual Analyst & Investor Day with Ambrx Biopharma, featuring Hope S. Rugo, MD, FASCO [Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education, UCSF] and Paula R. Pohlmann, MD, MSc, PhD (MD Anderson Cancer Center) who will discuss the current HER2 positive breast cancer treatment landscape, unmet medical need, and urgency for new treatments.
The event will also feature an update from the Ambrx management team on ARX788, its proprietary antibody drug conjugate (ADC) targeting HER2, and its plans for clinical development.
A live question and answer session will follow the formal presentations.